Teva Pharmaceutical Industries (NYSE:TEVA) Updates FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) issued an update on its FY 2025 earnings guidance on Saturday morning. The company provided earnings per share guidance of 2.450-2.650 for the period, compared to the consensus earnings per share estimate of 2.560. The company issued revenue guidance of $16.8 billion-$17.2 billion, compared to the consensus revenue estimate of $17.2 billion.

Teva Pharmaceutical Industries Trading Up 2.1%

Shares of Teva Pharmaceutical Industries stock traded up $0.36 during mid-day trading on Thursday, hitting $16.91. The stock had a trading volume of 3,297,589 shares, compared to its average volume of 9,981,277. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $22.80. The firm has a 50-day moving average of $15.37 and a two-hundred day moving average of $17.38. The firm has a market cap of $19.17 billion, a P/E ratio of -11.64, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business had revenue of $3.89 billion during the quarter, compared to analysts' expectations of $3.99 billion. During the same quarter in the prior year, the business posted $0.48 EPS. The company's revenue for the quarter was up 1.9% on a year-over-year basis. Sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TEVA. Bank of America boosted their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Barclays lowered their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Thursday. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Buy" and a consensus price target of $24.43.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

An institutional investor recently raised its position in Teva Pharmaceutical Industries stock. AQR Capital Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 24.6% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,955 shares of the company's stock after purchasing an additional 4,732 shares during the quarter. AQR Capital Management LLC's holdings in Teva Pharmaceutical Industries were worth $368,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.